Improving fundamentals and stabilizing technical baseline. Base building process active. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Sun Pharmaceutical Industries Limited (SUNPHARMA)•Updated yesterday
🛡️ Sound Structural Profile: In FY2026, Sun Pharmaceutical Industries Limited maintains a stable earnings trajectory, with 5.0% YoY growth in reported PAT to ₹11,508.6 Cr and a CFO/PAT ratio of 1.08 indicating cash-backed profitability. Historical monitoring signals around margin compression and capex efficiency are currently easing as operating efficiency stabilizes and non-operational reliance recedes. Balance sheet integrity is strong, with D/E at 0.05 and operating cash flows of ₹12,419.2 Cr providing financial capacity despite 118.3% YoY debt growth. Temporary working-capital friction—reflected in receivable days rising to 93.9 and a 9.8% operating leverage gap—remains contained, keeping Sun Pharmaceutical Industries Limited within Flagium’s stable surveillance range.
- ✓Risk score improved (QoQ change: -5 pts)
- ✓Profitability margins pressure eased (Industrial Margin Stress resolved)
- ✓Working Capital Expansion resolved this quarter (8 pts)
- ✗Growth expectations are demanding
- ✓Market structure is neutral/stabilizing
- ✗Institutional flow regime is Neutral (0.06σ)
- ✗Share price is down -3.3% this quarter (from ₹1,816.6 on 30 Sept to ₹1,757.5)
- 🟢No severe forensic red flags active for SUNPHARMA
- 🟢Industrial Margin Stress resolved in latest filing; verify sustainability in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 5.6 ptsGrowth Sustainability
- 2.4 ptsCompetitive Position
- 2.0 ptsBalance Sheet Stress
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +0.71% | -1.46% | +2.17% |
| 1 Month | -4.38% | -6.69% | +2.31% |
| 6 Months | -2.81% | +6.82% | -9.63% |
| 1 Year | +4.86% | +8.93% | -4.07% |
| 2 Year | -6.17% | +47.64% | -53.82% |
| 3 Year | +62.09% | +125.5% | -63.41% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure is receding in growth sustainability. This indicates that forensic pressure is currently receding. Risk levels are improving.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 0 → 10 over 12 quarters.
- Sustainability of earnings recovery
- Operating cash flow sustainability
- Working capital discipline
Risk Drivers (Active Warnings)
No active warnings detected.
Primary Driver & Insights
Forensic risk profile is stable. No severe operating or financial anomalies are currently pressure-testing business resilience.
Active Risk Objects (5)Free Preview (2 of 5)
SUNPHARMA: EBITDA margin compressed by 2.8 bps YoY.
Operating efficiency is stabilizing. The rate of margin deterioration has slowed.
Working capital expansion detected: Receivable days increased by 7.1%.
Working capital pressure is receding. Cash previously locked in operations is being released.
Unlock All 5 Forensic Signals (3 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 5 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Sun Pharmaceutical Industries Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Sun Pharmaceutical Industries Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-5.0 pts), driven by Industrial Margin Stress (-9.6 pts) and Working Capital Expansion (-8.0 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Watch
Watch
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Sun Pharmaceutical Industries Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 15,510 | 13,046 | 11,249 | 11,439 | — | — | — | — | — | — |
Inventories(₹ Cr) | 11,493 | 10,243 | 9,868 | 10,513 | — | — | — | — | — | — |
Trade Payables(₹ Cr) | 7,334 | 6,184 | 5,653 | 5,682 | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | 19,669 | 17,105 | 15,464 | 16,270 | — | — | — | — | — | — |
Working Capital / Sales(%) | 32.5% | 31.4% | 31.0% | 36.5% | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 119d | 115d | 113d | 133d | — | — | — | — | — | — |
Debtor Days (DSO)(days) | 94d | 87d | 82d | 94d | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 69d | 69d | 72d | 86d | — | — | — | — | — | — |
Creditor Days (DPO)(days) | 44d | 41d | 41d | 47d | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | +8.1% | +6.6% | -13.6% | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | +1.4% | -5.6% | -18.1% | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | +7.3% | -1.6% | -6.1% | — | — | — | — | — | +21.4% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | -911 | -3,107 | -2,525 | 3,554 | -5,595 | — | — | — | -1,365 | 764 |
Accrual Ratio (Accruals / Avg Assets)(%) | -0.9% | -3.5% | -3.0% | 4.4% | — | — | — | — | -2.2% | 1.3% |
Operating Cash Realisation (CFO / EBITDA)(%) | 75.6% | 97.5% | 104.8% | 51.8% | 99.3% | — | — | — | 69.4% | 70.1% |
Capitalisation Intensity (CWIP / Assets)(%) | 11.0% | 11.0% | 9.8% | 8.5% | — | — | — | — | — | — |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q1 FY2027 | 87.4% | +190 bps ↑ Operating efficiency gains | -20 bps ↓ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹1,758, the market expects this company to grow its net profits by 23.1% every year for the next 5 years. If you think the company will grow faster than 23.1%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Discounted Cash Flow (DCF) model, the market is pricing SUNPHARMA for 23.1% long-term growth versus 12.5% historical delivery. Current expectations appear demanding, and historical fundamentals provide strong support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides robust support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 23.1% | 12.5% | Demanding |
| Operating Margin (EBIT) | 26.9% | 25.6% | Demanding |
| Free Cash Flow Conversion | 52.6% | 74.1% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides partial evidence that these expectations are sustainable. Continued stronger profitability would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 3 distribution phase. Although institutional participation has improved, trend quality remains weakening and momentum is beginning to decay. Current price action does not yet confirm a decisive breakdown or a renewed advance.
What Is Driving Market Structure?
Market context is currently mixed, with conflicting price structure and flow signals.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on SUNPHARMA & 3 market anomalies weekly
See a sample issue →